Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer

British Journal of Cancer

Volumn 110, Issue 12, 2014, Pages 2975-2984

  Koussounadis, A ^a   Langdon, S P ^b   Harrison, D J ^c   Smith, V A ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Carboplatin; Ovarian cancer; Paclitaxel; Prognosis; Xenograft

Indexed keywords

CARBOPLATIN; FANCONI ANEMIA GROUP D2 PROTEIN; HEAT SHOCK PROTEIN 70; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; PACLITAXEL; PROTEIN P130; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER PROGNOSIS; CANCER SIZE; CELL CYCLE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPAIR; DNA REPLICATION; DRUG RESPONSE; DRUG SENSITIVITY; ENDOMETRIOID CARCINOMA; EXCISION REPAIR; FEMALE; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION; GLUTATHIONE METABOLISM; IN VIVO STUDY; METABOLIC REGULATION; MOUSE; NONHUMAN; OVARY ADENOCARCINOMA; OVARY CANCER; OVERALL SURVIVAL; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SINGLE DRUG DOSE; TUMOR XENOGRAFT; UPREGULATION; WNT SIGNALING PATHWAY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARBOPLATIN; CELL CYCLE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; ENERGY METABOLISM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; WNT SIGNALING PATHWAY;

EID: 84902537661     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.258     Document Type: Article

References (39)

1. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson Jr JA, Marks JR, Dressman HK, West M, Nevins JR (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357. (Pubitemid 43128862
2. Blagosklonny MV, Giannakakou P, el-Deiry WS, Kingston DG, Higgs PI, Neckers L, Fojo T (1997) Raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death. Cancer Res 57: 130-135. (Pubitemid 27020341
3. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351: 2519-2529
4. Crijns AP, Fehrmann RS, De Jong S, Gerbens F, Meersma GJ, Klip HG, Hollema H, Hofstra RM, te Meerman GJ, De Vries EG, van Der Zee AG (2009) Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med 6: E24
5. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E (1992) ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84: 1512-1517
6. Damia G, Filiberti L, Vikhanskaya F, Carrassa L, Taya Y, D'incalci M, Broggini M (2001) Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia 3: 10-16
7. Dorfman MD, Kerr B, Garcia-Rudaz C, Paredes AH, Dissen GA, Ojeda SR (2011) Neurotrophins acting via TRKB receptors activate the JAGGED1-NOTCH2 cell-cell communication pathway to facilitate early ovarian development. Endocrinology 152: 5005-5016
8. Du P, Kibbe WA, Lin SM (2008) Lumi: A pipeline for processing Illumina microarray. Bioinformatics 24: 1547-1548. (Pubitemid 351911712
9. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868. (Pubitemid 29003722
10. Faratian D, Zweemer AJ, Nagumo Y, Sims AH, Muir M, Dodds M, Mullen P, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP (2011) Trastuzumab and pertuzumab produce changes in morphology and oestrogen receptor signalling in ovarian cancer xenografts revealing new treatment strategies. Clin Cancer Res 17: 4451-4461
11. Fink D, Aebi S, Howell SB (1998) The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4: 1-6. (Pubitemid 28062870
12. Fong CW, Zhua MS, McKie AB, Ling SH, Mason V, Li R, Yusoff P, Lo TL, Leung HY, So SK, Guy GR (2006) Sprouty 2, an inhibitor of mitogenactivated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res 66: 2048-2058
13. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869-1883
14. Golan T, Yaniv A, Bafico A, Liu G, Gazit A (2004) The human Frizzled 6 (HFz6) acts as a negative regulator of the canonical Wnt . b-catenin signaling cascade. J Biol Chem 279: 14879-14888. (Pubitemid 38618878
15. Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC, van Der Burg ME, Stoter G, Nooter K, Berns EM (2006) Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 118: 1963-1971
16. Helleman J, Smid M, Jansen MP, van Der Burg ME, Berns EM (2010) Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: The big picture. Gynecol Oncol 117: 170-176
17. Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nat Protoc 4: 44-57
18. International Collaborative Ovarian Neoplasm Group (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-Agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet 360: 505-515
19. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M (2012) KEGG for integration and interpretation of large-scale molecular datasets. Nucleic Acids Res 40: D109-D114
20. Konstantinopoulos PA, Cannistra SA, Fountzilas H, Culhane A, Pillay K, Rueda B, Cramer D, Seiden M, Birrer M, Coukos G, Zhang L, Quackenbush J, Spentzos D (2011) Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PLoS One 6: E18202
21. Kriajevska M, Fischer-LarsenM, Moertz E, Vorm O, Tulchinsky E, Grigorian M, Ambartsumian N, Lukanidin E (2002) Liprin b1, a member of the family of LAR transmembrane tyrosine phosphatase-interacting proteins, is a new target for the metastasis-Associated protein S100A4 (Mts1). J Biol Chem 277: 5229-5235
22. Li J, Wood 3rd WH, Becker KG, Weeraratna AT, Morin PJ (2007) Gene expression response to cisplatin treatment in drug-sensitive and drugresistant ovarian cancer cells. Oncogene 26: 2860-2872. (Pubitemid 46701436
23. Liu J, Campen A, Huang S, Peng SB, Ye X, Palakal M, Dunker AK, Xia Y, Li S (2008) Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data. BMC Med Genomics 1: 39
24. Pabla N, Huang S, Mi QS, Daniel R, Dong Z (2008) ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 283: 6572-6583
25. Plenchette S, Cheung HH, Fong WG, LaCasse EC, Korneluk RG (2007) The role of XAF1 in cancer. Curr Opin Investig Drugs 8: 469-476. (Pubitemid 46868069
26. Ren A, Yan G, You B, Sun J (2008) Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells. Cancer Res 68: 2266-2274. (Pubitemid 351521800
27. Schaaf G, Hamdi M, Zwijnenburg D, Lakeman A, Geerts D, Versteeg R, Kool M (2010) Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumours carrying a mutated RAS gene. Cancer Res 70: 762-771
28. Shah MA, Schwartz GK (2001) Cell cycle-mediated drug resistance: An emerging concept in cancer therapy. Clin Cancer Res 7: 2168-2181. (Pubitemid 32751613
29. Shahzad MM, Lopez-Berestein G, Sood AK (2009) Novel strategies for reversing platinum resistance. Drug Resist Updat 12: 148-152
30. Sherman-Baust CA, Becker KG, Wood Iii WH, Zhang Y, Morin PJ (2011) Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin. J Ovarian Res 4: 21
31. Siliņa K, Zayakin P, Kalniņa Z, Ivanova L, Meistere I, Endzeliņš E, A-bols A, Stengre-vics A, Leja M, Ducena K, Kozirovskis V, Line-A (2011) Spermassociated antigens as targets for cancer immunotherapy: Expression pattern and humoral immune response in cancer patients. J Immunother 34: 28-44
32. Sims AH, Zweemer AJM, Nagumo Y, Faratian D, Muir M, Dodd M, Um I, Kay C, Hasman M, Harrison DJ, Langdon SP (2012) Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. Br J Cancer 106: 1779-1789
33. Smyth GK (2005) Limma: Linear models for microarray data. In Bioinformatics and Computational Biology Solutions Using R and Bioconductor, Gentleman RRW, Carey V, Dudoit S, Irizarry R, Huber Huber WRW (eds) pp 397-420. Springer: New York
34. Taylor KJ, Sims AH, Liang L, Faratian D, Muir M, Walker G, Kuske B, Dixon JM, Cameron DA, Harrison DJ, Langdon SP (2010) Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-Treated patients with breast cancer. Breast Cancer Res S12: R39
35. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I. Australian Ovarian Cancer Study GroupGertig D, DeFazio A, Bowtell DD (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208
36. Vanhecke E, Adriaenssens E, Verbeke S, Meignan S, Germain E, Berteaux N, Nurcombe V, Le Bourhis X, Hondermarck H (2011) Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumour cell survival. Clin Cancer Res 17: 1741-1752
37. Wennemers M, Bussink J, Scheijen B, Nagtegaal ID, van Laarhoven HW, Raleigh JA, Varia MA, Heuvel JJ, Rouschop KM, Sweep FC, Span PN (2011) Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response. Breast Cancer Res 13: R82
38. Yanagie H, Hisa T, Ogata A, Miyazaki A, Nonaka Y, Nishihira T, Osada I, Sairennji T, Sugiyama H, Furuya Y, Kidani Y, Takamoto S, Takahashi H, Eriguchi M (2009) Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complexresistant ovarian cancer cells in vitro. Biomed Pharmacother 63: 553-560
39. Yoon H, Lim JH, Cho CH, Huang LE, Park JW (2011) CITED2 controls the hypoxic signaling by snatching p300 from the two distinct activation domains of HIF-1a. Biochim Biophys Acta 1813: 2008-2016.